



Curriculum Vitae- Professor Pilar GARRIDO, MD, PhD  
Associate Professor  
Head, Thoracic Tumour Unit  
Medical Oncology Department  
Hospital Universitario Ramón y Cajal,  
Facultad de Medicina, Universidad de Alcalá  
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)  
Madrid, Spain

**Personal Data**

Name: Pilar Garrido López

Date of birth: January 19<sup>th</sup>, 1962

Place of birth: Madrid, Spain

Country of Citizenship: Spain

Hospital Address: Medical Oncology Department  
Hospital Universitario Ramón y Cajal  
Carretera Colmenar Viejo km 9100  
28034, Madrid, Spain

Licensed physician:  
1986 Madrid Medical License: 282837505

**Education:**

1980-1986 School of Medicine - Universidad Autónoma de Madrid, Madrid Spain.

**Certificates:**

1986 Degree in Medicine and Surgery, Universidad Autónoma de Madrid

1990 Board Certified in Medical Oncology. Spanish Board of Medical Oncology

1993 Ph.D. Universidad Autónoma de Madrid. Madrid, Spain.

2014 Healthcare Management Program. IESE Business School. Madrid, Spain.

2014-15. Clinical Management Program in Medical Oncology. Universitat Pompeu Fabra.

---

**Postdoctoral Training:**

1987-1990 Residency, Department of Medical Oncology, Hospital Universitario La Paz, Universidad Autónoma de Madrid. Madrid, Spain.

**Positions and Appointments:**

1991-1998 Clinical Assistant Physician, Department of Medical Oncology,

	Hospital Universitario Ramón y Cajal, Universidad de Alcalá. Madrid, Spain.
1998-2009	Senior Clinical Assistant Physician, Thoracic Tumors Unit, Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá. Madrid, Spain
2009-	Head, Thoracic Tumours Unit, Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá. Madrid, Spain
2015-	Co-Director Chronic Disease and Cancer Research area IRYCIS (Instituto Ramón y Cajal de Investigación Sanitaria). Hospital Universitario Ramón y Cajal, Universidad de Alcalá. Madrid, Spain
2016-	Associate Professor, Medicine Department, Universidad de Alcalá. Madrid, Spain.

**Current Institutional Responsibilities:**

2009-	Head, Thoracic Tumours Unit, Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá. Madrid, Spain
2014-	Member of the Spanish National Cancer Strategy Board
2015-	Co-Director Chronic Disease and Cancer Research area IRYCIS (Instituto Ramón y Cajal de Investigación Sanitaria). Hospital Universitario Ramón y Cajal, Universidad de Alcalá. Madrid, Spain
2015-,	President of the Spanish Medical Oncology Training National Commission
2015 -,	President of the Spanish National Health Specialties Advisory Board
2015-,	Executive Board Member Spanish Federation Medical Specialties (FACME) 2015-
2016-,	Associate Professor, Medicine Department, Universidad de Alcalá. Madrid, Spain.
2016-	Member of CiberOnc as PI
2017-	Member of Spanish Minister of Health Advisory Council

**Scientific and Medical Societies:**

- ❖ European Society for Medical Oncology - ESMO

Past activities within ESMO

- ESMO meetings:
  - Advisory council member ESMO Congress 2014
  - Scientific committee member: European Lung Cancer Conference (ELCC) 2016, 2018 and ESMO 2016

- Chair non-metastatic NSCLC track ESMO Congress 2017
- Chair ESMO Scientific Committee ELCC 2019
- Press Officer ESMO Congress 2018 and ESMO Asia Congress 2019
- Nominating Committee member 2017-2018.
- Executive Board member 2018.

Current:

- Faculty Member for the Chest Tumours 2009-
- ESMO Fellowship and Awards/ Fellowship Committee member 2014-
- Women for Oncology Task Force/ Committee member 2015-
- Press and Media Affairs Committee Chair 2018-
- Press Officer ESMO Congress 2019 and ESMO Asia Congress 2019
- ESMO Council member 2019-
- ELCC 2019. ESMO Chair Scientific Committee

❖ International Association for Study of Lung Cancer (IASLC)

Past activities within IASLC

- Membership Committee member 2015-2018
- WCLC 2015 Scientific Committee track member

Current

- Bylaws Committee member 2019-
- WCLC 2019 Regional Organizing Committee
- WCLC 2019 Scientific Committee Track Chair

❖ Spanish Medical Oncology Society –SEOM

Past activities within SEOM:

- Executive Board member 2001-2005
- Executive Board member 2009-2011
- President- elect 2011-2013
- President 2013-2015
- Board member of the Medical Oncology Training National Commission 2011-2015
- Scientific Committee Annual Congress:
  - Member 2010, 2011, 2012, 2013
  - Chair 2014, 2015

Current

- SEOM National Representative and Executive Board Member Spanish Federation Medical Specialties (FACME) 2015-
- Chair SEOM Women for Oncology Committee 2019-
- ❖ Spanish Lung Cancer Group (SLCG)
  - Executive Board member 2000-2010
- ❖ Spanish Cancer Research Association (AECC)
  - National Scientific Committee member 2017-
- ❖ Spanish Oncology Research Society (ASEICA)
- ❖ American Society Clinical Oncology (ASCO)

**Peer Review Evaluations:**

Spain: Spanish Cancer Research Association, Spanish Medicine and Health Products Agency. Instituto de Salud Carlos III National Evaluation Board 2015-2018

France: National Cancer Institute 2014.

Rater for the McMaster Online Rating of Evidence (MORE) System 2017-

**Editorial Boards**

Associate Editor Annals of Oncology

Editorial Board: Revista Educación Médica, New Medical Economics, Oncologia, Seminars in Oncology (Spanish versión)

Associate Editor Biomarkers Research Journal and World Journal of Respiriology

**Referee for scientific journals**

Ad-hoc reviewer: Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Lung Cancer, European Respiratory Journal, Journal of Clinical and Translational Oncology, Case Reports in Hematology, Expert Review of Anticancer Therapy.

**Research Support Role: grants as PI**

- PIE15/00050. Instituto Salud Carlos III. Spanish Government. "Discovery, validation and implementation of biomarkers for precision oncology" 2015-2018
- PI11/01572. Instituto Salud Carlos III. Spanish Government. "Use of Circulating tumor cells as a monitoring tool in locally advanced non-small cell lung cancer patients". 2012-2014.
- Fundación Mutua Madrileña: Lung cancer in women: influence of hormonal factors and clinico-pathologic correlation. 2010-2012

### Publications list (H Index 19)

1. Molina-Cerrillo J, Alonso-Gordoa T, Garrido P. Tumor-associated macrophages: "Good cop-bad cop". *Cancer*. 2019 Feb 12. doi: 10.1002/cncr.32016. [Epub ahead of print]
2. Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepatis R, Wu X, Fandi A, Paz-Ares L. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. *Eur J Cancer* 2019 Feb;108:120-128.
3. Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L. Clinical utility of plasma-based digital next-generation sequencing in patients with advanced-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. *Ann Oncol*. 2019 Feb 1;30(2):290-296.
4. Peters S, Dafni U, Boyer M, De Ruyscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino M. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). *Ann Oncol*. 2019 Feb 1;30(2):161-165
5. Rosa-Rosa JM, Caniego-Casas T, Leskela S, Muñoz G, Del Castillo F, Garrido P, Palacios J. Modified SureSelect (QXT) Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples. *Biol Proced Online*. 2018 Oct 12;20:19.
6. Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E. Lung cancer in Spanish women: The WORLD07 project. *Eur J Cancer Care* 2019 Jan;28(1):e12941.
7. Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. *Clin Cancer Res*. 2019 Jan 1;25(1):64-72.

8. Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. *Lancet Respir Med*. 2018 ;6(10):771-781.
9. Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. *Clin Cancer Res*. 2018;24(22):5543-555
10. Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM. A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). *Lung Cancer*. 2018 Jun;120:27-33.
11. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Filip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA Oncol*. 2018 Mar 1;4(3):351-357.
12. Garrido P, Olmedo ME, Gómez A, Paz Ares L, López-Ríos F, Rosa-Rosa JM, Palacios J. Treating KRAS-mutant NSCLC: latest evidence and clinical consequences. *Ther Adv Med Oncol*. 2017 Sep;9(9):589-597.
13. Garrido P, Aldaz A, Vera R, Calleja MA, de Álava E, Martín M, Matías-Guiu X, Palacios J. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. *Clin Transl Oncol*. 2018 Apr;20(4):443-447.
14. Gorospe L, Ayala-Carbonero AM, Olmedo-García ME, Gómez-Rueda A, Palka M, Mezquita L, Garrido-López P. Nivolumab-induced pneumonitis complicated by cyst formation. *Lung Cancer*. 2018 Aug;122:258-259.
15. Gorospe L, Ayala-Carbonero AM, Farfán-Leal FE, Muñoz-Molina GM, Olmedo-García ME, Gómez-Rueda A, Garrido-López P. NUT midline carcinoma causing critical stenosis of the coronary arteries: CT demonstration. *Surgery*. 2018; Feb;163(2):480-481
16. Conde E, Caminoa A, Dominguez C, Calles A, Walter S, Angulo B, Sánchez E, Alonso M, Jimenez L, Madrigal L, Hernando F, Sanz-Ortega J, Jimenez B, Garrido P, Paz-Ares L, de Castro J, Hernandez S, Lopez-Rios F. Aligning digital CD8(+) scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. *Histopathology*. 2018 Jan;72(2):270-284.

17. Garrido P, Chouaki N, Serke M, Giraud P, Ricardi U, Vallejo C, Visseren-Grul C, Soldatenkova V, Novello S. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. *ESMO Open*. 2017 Mar 9;2(1):e000141.
18. Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. *Clin Transl Oncol*. 2017 Dec;19(12):1537-1542.
19. Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov 7, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. *JAMA*. 2017;317(18):1844-1853.
20. Garrido P, Sánchez M, Belda Sanchis J, Moreno Mata N, Artal Á, Gayete Á, Matilla González JM, Galbis JM, Isla D, Paz-Ares L, Seijo LM. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. *Arch Bronconeumol*. 2017 Apr 14. pii: S0300-2896(17)30068-6.
21. Viñolas N, Garrido P, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E. Lung Cancer in never smokers: a sub-analysis of the Spanish Female-Specific database WORDL07. *Cancer Invest*. 2017 May 28;35(5):358-365.
22. Rivera F, Andres R, Felip E, Garcia-Campelo R, Lianes P, Llombart A, Piera JM, Puente J, Rodriguez CA, Vera R, Virizuela JA, Martin M, Garrido P. Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. *Clin Transl Oncol*. 2017 Apr;19(4):508-518.
23. Caravaca-Fontán F, Martínez-Sáez O, Pampa-Saico S, Olmedo ME, Gomis A, Garrido P. Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis. *Med Clin (Barc)*. 2017 Feb 9;148(3):121-124.
24. Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R; Spanish Lung Cancer Group. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. *Clin Lung Cancer*. 2017 Mar;18(2):178-188.e4.
25. Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, García-Campelo R, Juan O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MÁ, Cobo M, Paz-Ares L, Trigo JM, de Castro J. A consensus statement on the gender perspective in lung cancer. *Clin Transl Oncol*. 2017 May;19(5):527-535.
26. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A,



- Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. *J Thorac Oncol*. 2017 Feb;12(2):194-207.
27. Sacristán JA, Dilla T, Garrido P, Avendaño C, Cruz-Hernández JJ, Espinosa J, Comellas M, Lizán L. Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival? *J Comp Eff Res*. 2017 Sep;6(6):491-495
28. Salvador J, Urtasun JA, Duart FJ, García-Campelo R, Carbonero RG, Lianes P, Llombart A, Casado DI, Piera JM, Mateu MM, Puente J, Rivera F, Rodríguez CA, Virizuela JA, Martín M, Garrido P. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. *Clin Transl Oncol*. 2017 Mar;19(3):341-356. doi: 10.1007/s12094-016-1535-8. Epub 2016 Aug 25. Erratum in: *Clin Transl Oncol*. 2017 Feb 27;; *Clin Transl Oncol*. 2017 Apr;19(4):525.
29. De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-odina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D. Long-term survival in advanced non-squamous non small cell lung cancer patients treated with first-line bevacizumab-based therapy. *Clin Transl Oncol*. 2017 Feb;19(2):219-226.
30. Garrido P, Palacios J. Necitumumab in squamous non-small-cell lung cancer: how to move forward? *Ann Oncol*. 2016 Aug;27(8):1374-6.
31. Isla D, Felip E, Viñolas N, Provencio M, Majem M, Artal A, Bover I, Lianes P, De Las Peñas R, Catot S, DE Castro J, Blasco A, Terrasa J, Gonzalez-Larriba JL, Juan O, Dómine M, Bernabe R, Garrido P. Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. *Anticancer Res*. 2016 Dec;36(12):6647-6653.
32. Sacristán JA, Lizan L, Comellas M, Garrido P, Avendaño C, Cruz-Hernández JJ, Espinosa J, Dilla T Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. *Adv Ther*. 2016 Nov;33(11):2059-2068.
33. Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, Molins López-Rodó L, Rodríguez Suárez PM, Sánchez de Cos Escuin J, Barreiro E, Borrego Pintado MH, Disdier Vicente C, Flandes Aldeyturriaga J, Gámez García P, Garrido López P, León Atance P, Izquierdo Elena JM, Novoa Valentín NM, Rivas de Andrés JJ, Royo Crespo Í, Salvatierra Velázquez Á, Seijo Maceiras LM, Solano Reina S, Aguiar Bujanda D, Avila Martínez RJ, de Granda Orive JI, de Higes Martinez E, Diaz-Hellín Gude V, Embún Flor R, Freixinet Gilart JL, García Jiménez MD, Hermoso Alarza F, Hernández Sarmiento S, Honguero Martínez AF, Jimenez Ruiz CA, López Sanz I, Mariscal deAlba A, Martínez Vallina P, Menal Muñoz P, Mezquita Pérez L, Olmedo García ME, Rombolá CA, San Miguel Arregui I, de Valle Somiedo Gutiérrez M, Triviño Ramírez AI, Trujillo Reyes JC, Vallejo C, Vaquero Lozano P, Varela Simó G, Zulueta JJ. Executive summary of the SEPAR recommendations for

- the diagnosis and treatment of non-small cell lung cancer. *Arch Bronconeumol*. 2016 Jul; 52(7): 378-388.
34. Álvarez FV, Trueba IM, Sanchis JB, López-Rodó LM, Rodríguez Suárez PM, de Cos Escuín JS, Barreiro E, Henar Borrego Pintado M, Vicente CD, Aldeyturriaga JF, Gámez García P, Garrido López P, León Atance P, Izquierdo Elena JM, Novoa Valentín NM, Rivas de Andrés JJ, Crespo ÍR, Velázquez ÁS, Seijo Maceiras LM, Reina SS, Bujanda DA, Ávila Martínez RJ, de Granda Orive JI, Martínez EH, Gude VD, Flor RE, Freixinet Gilart JL, García Jiménez MD, Alarza FH, Sarmiento SH, Honguero Martínez AF, Jiménez Ruiz CA, Sanz IL, Mariscal de Alba A, Martínez Vallina P, Menal Muñoz P, Pérez LM, Olmedo García ME, Rombolá CA, Arregui ÍS, Somiedo Gutiérrez MD, Triviño Ramírez AI, Trujillo Reyes JC, Vallejo C, Lozano PV, Simó GV, Zulueta JJ. Recommendations of the Spanish Society of Pneumology and Thoracic Surgery on the diagnosis and treatment of non-small-cell lung cancer. *Arch Bronconeumol*. 2016 May;52 Suppl 1:2-62.
  35. Camps C, Albanell J, Antón A, Aranda E, Carrato A, Cassinello J, Castellano D, Cruz JJ, Garrido P, Guillem V, Grávalos C, López G, Llorente C, Lorenzo A, Lluch A, Ignacio E, Díaz-Rubio E. Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. *J Natl Compr Canc Netw*. 2016 May;14(5):553-8.
  36. Sacristán JA, Aguarón A, Avendaño-Solá C, Garrido P, Carrión J, Gutiérrez A, Kroes R, Flores A Patient involvement in clinical research: why, when, and how. *Patient Preference Adherence*. 2016 Apr 27;10:631-40.
  37. Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). *ESMO Open*. 2016 Dec 7;1(6):e000107.
  38. Dilla T, Lizán L, Paz S, Garrido P, Avendaño C, Cruz Hernández JJ, Espinosa J, Sacristán JA. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. *Patient preference and adherence* 2015;9:1-7.
  39. Felip E, Concha A, de Castro J, Gomez Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. *Clin Transl Oncol* 2015; 17: 103-12
  40. Garrido P, Engel-Riedel W, Serke M, Giraud P, Ricardi U, Vallejo C, Visseren-Grul C, Ameryckx S, Soldatenkova V, Chouake N, Novello S. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer. *Lung Cancer* 2015; 88: 160-66.
  41. De Castro J, García R, Garrido P, Isla D, Massuti B, Blanca B, Vázquez J. Therapeutic potential of denosumab in patients with lung cancer: Beyond prevention of skeletal complications. *Clin Lung Cancer* 2015;16(6): 431-436

42. Conde E, Suarez Gauthier A, Benito A, Garrido P, García Campelo R, Biscuola M, Paz Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gomez Román J, Hidalgo M, López Ríos F. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. *PLoS One* 2014;9 (9): e107200.
43. Garrido P, Rodriguez CA. SEOM guidelines 2014: improving quality to increase its usefulness. *Clin Transl Oncol* 2014; 16: 1023-1024
44. Remon J, Molina Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de Castro J, Artal A, Sanchez MJ. Lung cancer in women: an overview with special focus on Spanish women. *Clin Transl Oncol* 2014;16(6): 517-28
45. Cañizares MA, Matilla JM, Cueto A, Algar J, Muguruza I, Moreno Mata N, Moreno Balsalobre R, Guijarro R, Arrabala R, Garcia Fontan E, Gonzalez Piñeiro A, Garcia Yuste M, EMETNE-SEPAR members. Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. *Thorax* 2014;69: 648-53.
46. Camps C, Felip E, García Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. *Clin Transl Oncol* 2013; 15: 977-984.
47. Garrido P, Rosell R, Arellano A, Andreu F, Domine M, Perez Casas A, Cardenal F, Arnaiz MM, Morán T, Morera R, Isla D, Valencia J, Cobo M, Delgado R, García Gómez R, Calvo F, Zamora J, Ramos A, Massuti B. Randomized phase II trial non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer group 0008 study. *Lung Cancer* 2013; 81: 84-90. IF 3.737. Q1
48. Salvador J, Grávalos C, Albanell J, Barnadas A, Borrega P, García Mata J, Garrido P, Gonzalez Flores E, Isla D, Lomas M, Rodriguez Lescure A, Cruz JJ, Alba E. Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. *Clin Transl Oncol* 2012; 14: 820-26.
49. Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, Kohlhaeufel M. MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous MSCLC. *Lung Cancer* 2012; 76: 373-79.
50. Grávalos C, Salvador J, Albanell J, Barnadas A, Borrego P, García Mata J, Garrido P, Gonzalez Flores E, Isla D, Lomas M, Rodriguez Lescure A, Cruz JJ, Alba E on behalf of the Spanish Society for Medical Oncology (SEOM). Functions and workload of medical oncologists in Spain. *Clin Transl Oncol* 2012;14: 423-429.
51. Colomer R, Garrido P, de Álava E, García Alfonso P, Palacios J, Ariza A from the Multidisciplinary Working Group on Cancer Biomarkers of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). A new multidisciplinary Spanish Working Group on Cancer Biomarkers; presentation and aims. *Clin Transl Oncol* 2012; 14:323-24
52. Garrido P, de Castro J, Concha A, Felip E, Isla D, Lopez Rios F, Paz Ares L, Ramírez J, Sanz J, Gomez JJ. Guidelines for biomarker testing in advanced non-small-cell lung

- cáncer: a National Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). *Clin Transl Oncol* 2012; 14: 338-349
53. Gomez Martín C, Concha A, Corominas JM, García Caballero T, García García E, Iglesias M, López JA, Ramón y Cajal S, Rojo F, Palacios J, Vera Sempere F, Aranda E, Colomer R, García Alfonso P, Garrido P, Rivera F, López Rios F. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. *Clin Transl Oncol* 2011; 13: 636-51.
  54. Vallejo Ocaña C, Garrido López P, Muguruza Trueba I. Multidisciplinary approach in stage III non-small-cell-lung cancer: standard of care and open questions. *Clin Transl Oncol* 2011; 13: 629-35.
  55. Longo F, Riquelme A, Rodriguez M, Olmedo ME, Garrido P. Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer. *Onkologie* 2011; 34: 326-328.
  56. Gascón P, Almenárez J, Artal A, Camps C, Fírvida J, Garrido P, González Larriba JL, Montalar J. Management of lung cáncer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). *Clin Transl Oncol* 2011;13: 328-34.
  57. Salazar F, Molina MA, Sanchez Ronco M, Morán T, Ramírez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertrán Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sancez JJ, Tarón M, Rosell R. First-line therapy and methylation status of CHFR in seum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell-lung cancer patients. *Lung Cancer* 2011; 72: 84-91.
  58. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. *Lancet Oncology* 2010; 11: 733-740.
  59. Krakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, Von Pawel J, Sun X, Bennouna J, Santoro A, Biesna B, Delgado FM, Salhi Y, Vaissiere N, Hansen O, Tan EH, Quoit E, Garrido P, Douillard JY. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. *Journal of Clinical Oncology* 2010; 28: 2167-2173.
  60. Trigo JM, Garrido P, Felip E, Isla D. SEOM clinical guidelines for the treatment of non-small cell lung. *Clin Transl Oncol*. 2009 May; 11(5): 284-9.
  61. Provencio M, Sanchez A, Garrido P, Valcarcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. *Clinical Lung Cancer* 2010; 11: 91-97.
  62. Garrido P, Rosell R, Massuti B, Cardenal F, Arberola V, Domine M, Maeztu I, Ramos A, Arellano. Predictors of long-term survival in lung cancer patients included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. *Clinical Lung Cancer* 2009; 10: 180-186.
  63. Felip E, Garrido P, Trigo JM, López Brea M, Paz-Ares L, Provencio M, Isla D. SEOM guidelines for the management of non-small cell lung cancer. *Clinical and Translational Oncology* 2009; 11:284-289.

64. Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, Stahel R, Trigo JM, Wei J, Taron M. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small cell lung cancer. *Clin Lung Cancer* 2008; 9 : 72-82.
65. Guillén Ponce C, Garrido López MP, Molina Garrido MJ, Muñoz Molina G, Carrato A. Panhypopituitarism as first manifestation of a lung cancer. *Clin Transl Oncol*. 2007 an;9(1):53-5.
66. Garrido P, Gonzalez Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cerdal F, Domine M, Barcelo JR, Tarragona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernandez Trancho F, Massuti B, Sanchez Ronco, M, Rosell, R. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB non-small cell lung patients: the Spanish Lung Cancer Group trial 9901. *Journal of Clinical Oncology* 2007; 25 : 4736-4742.
67. Felip E, Rosell, R, Domine M, Santome L, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mañe JM, Baselga J. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive stage small cell lung cancer: a Spanish Lung Cancer Group phase II study. *Annals of Oncology* 2003; 14 : 1549-1554.
68. Nogue-Aliguer M, Carles J, Arribi A, Juan O, Alonso L, Font A, Mellado B, Garrido P, Saenz A. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract. *Cancer* 2003; 97: 2180-2186.
69. Cardenal F, Domine M, Massutti B, Carrato A, Felip E, Garrido P, Juan O, Artal A, Barreto I, Lopez-Vivanco G, Balcells M, Rosell R. Three week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. *Lung Cancer* 2003; 39: 201-207.
70. Gonzalez-Martin A, Crespo C, Garcia-Lopez JL, Pedraza M, Garrido P, Lastra E, Moyano A. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. *Gynecologic Oncology* 2002; 84: 368-373.
71. Feliu J, Gonzalez Baron M, Zamora P, Garcia Alfonso P, Garcia Giron C, Blanco E, Belon J, Garrido P, Jara C, Ruiz A, Vincent JM, Espinosa E. Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. *Oncology* 1997; 54 sup. 1: 30-37.
72. Feliu J, Gonzalez Baron M, Chacon JL, Espinosa E, Garrido P, Castro J, Escobar Y, Colmenarejo A, Jara C, Garcia Girón C, Espinosa J, Ordoñez A. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. *Cancer Chemotherapy and Pharmacology* 1996; 38: 191-194.
73. Feliu J, González Barón M, García-Girón C, Espinosa E, Garcia-Alfonso P, Belon J, Blanco E, Garrido P, Ordoñez A, Gomez-Navarro J, Zamora P. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. *Cancer* 1996; 78: 211-216
74. González-Barón M, Feliu J, De la Gandara I, Espinosa E, Colmenarejo A, Martinez B, Blanco E, García –Girón C, Juarez F, Garrido P, Ordoñez A, Zamora P, Efficacy of oral

- tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. *European Journal of Cancer* 1995; 31: 13-14.
75. Gonzalez-Baron M, Feliu J, Espinosa E, García Girón C, Chacon I, Garrido P, Colmenarejo A, Ordoñez A, Zamora P. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group. *Cancer Chemotherapy and Pharmacology* 1995; 36: 255-258
  76. González Barón M, Feliu J, Espinosa E, García Girón C, Blanco E, Garrido P, Colmenarejo A, Ordoñez A, Moyano A, De la Gandara I, Zamora. Comparison two chemotherapeutic regimens: mitomycin, vindesine, cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non small cell lung cancer. *Annals of Oncology* 1994; 5: 323-327
  77. González Barón M, Feliu J, Espinosa E, García Girón C, Chacon JI, Garrido P, Colmenarejo A. FLEP (5-fluoracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer. *European Journal Cancer* 1994; 30: 1733.
  78. González Barón, M, Artal A, Garrido P, García Girón C, Ordoñez A, Feliú J, Berrocal A, Baron JM. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin. *American Journal of Clinical Oncology* 1993; 16: 310-314.
  79. Gonzalez Baron M, Garcia Girón C, Zamora P, García de Paredes ML, Feliú J, Ordoñez A, Artal A, Garrido P, Chacon JI. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. *American Journal of Clinical Oncology* 1992; 15: 23-28.
  80. Feliú J, Gonzalez-Baron M, Berrocal A, Artal A, Ordoñez A, Garrido P, Zamora P, Garcia de Paredes ML, Montero JM. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. *American Journal of Clinical Oncology* 1992; 15: 436-440.
  81. Garrido López MP, Artal Cortés A, Zamora Auñón P. Autoimmune hemolytic anemia and carcinoma of the larynx: an exceptional association. *Rev Clin Esp.* 1992 Sep;191(4):207-8.
  82. González Baron, M., Chacon JI, Garcia Girón, C, Ordoñez Gallego, A., Garcia de Paredes, ML, Feliu J, Zamora P, Herranz C., Garrido P., Artal A. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam. *Acta Oncologica* 1991; 30; 623-627.
  83. Feliu J, Gonzalez Baron, M Artal A, Ordoñez A, Cebreiros I, Martin G, Garrido P, Chacon I, Montero Garcia JM. Bone marrow examination in small cell lung cancer. When is it indicated?. *Acta Oncologica* 1991; 30 : 587-591.
  84. Feliu J, Gonzalez Baron M, Berrocal M, Baron JM, Artal A, Garrido P, Ordoñez, A, Jalon JI. Cáncer de pulmón en enfermos menores de 40 años: ¿un problema diferente?. *Medicina Clínica* 1991; 97: 373-376.
  85. Artal A, Garrido P, Berrocal A, Barón JM, Espinosa E, De la Gandara I, , Juarez S, Estudio descriptivo de la asistencia a enfermos oncológicos en el servicio de urgencias de un hospital general. *Revista Clínica Española* 1991; 887: 345-348.
  86. Gonzalez-Baron, M., Vicente J., Tomas M., Martin G., Martorell V., Garcia-Giron, C., Garrido P., Gavilan J., Zamora, P. Phase II trial of cisplatin and tegafur (Ftorafur) as

- initial therapy in squamous-cell carcinoma of the head and neck. American Journal of Clinical Oncology-Cancer Clinical Trials 1990; 13: 312-314.
87. Feliu J., De la Gandara I., Garrido P., Gonzalez Baron, M. Somatostatin analogues and pancreatic acinar cell carcinoma: an alternative in symptomatic treatment? American Journal of Gastroenterology 1990; 85; 1539-1540.
  88. García-Girón, C, Artal A., Garrido P., González Barón, M. Control de adenocarcinoma suprarrenal y síndrome de Cushing con ketoconazol. Medicina Clinica 1989 ; 92: 36-37.
  89. Artal A., Berrocal A., Feliu J., Garrido P. Timoma y agranulocitosis: una asociación excepcional. Medicina Clínica 1989; 93 : 156-157.